

# David N Louis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6904320/publications.pdf>

Version: 2024-02-01

80  
papers

43,338  
citations

50566

48  
h-index

81351

76  
g-index

96  
all docs

96  
docs citations

96  
times ranked

41739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Paul Kleihues (1936–2022), neuropathology innovator and entrepreneur. <i>Brain Pathology</i> , 2022, 32, e13073.	2.1	0
2	Atretic cephalocele: Report of an infrequent dermatopathologic finding. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1439-1441.	0.7	1
3	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	13.5	210
4	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
5	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 196-206.	1.2	21
6	A half century of change in diagnostic neuropathology: from the giants of yore to current brain tumor classification. <i>Human Pathology</i> , 2020, 95, 161-168.	1.1	2
7	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020, 222, 1955-1959.	1.9	72
8	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. <i>Brain Pathology</i> , 2020, 30, 863-866.	2.1	168
9	Roses and rosettes—the two sides of James Homer Wright. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 286-292.	0.2	0
10	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	3.9	344
11	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	2.1	363
12	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	13.5	1,408
13	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. <i>Acta Neuropathologica</i> , 2019, 137, 683-687.	3.9	170
14	Characterization of applicants for residency training in pathology: Does diversity exist?. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 23-25.	0.6	3
15	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	0.6	25
16	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	5.8	56
17	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. <i>Acta Neuropathologica</i> , 2018, 135, 639-642.	3.9	281
18	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	6.0	461

#	ARTICLE	IF	CITATIONS
19	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	3.9	298
20	A feast of reviews about brain and pituitary tumor pathology. <i>Brain Tumor Pathology</i> , 2018, 35, 49-50.	1.1	2
21	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). <i>Acta Neuropathologica</i> , 2018, 135, 481-484.	3.9	145
22	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. <i>Seminars in Neurology</i> , 2018, 38, 019-023.	0.5	30
23	PATH-32. BRAIN TUMOR CLASSIFICATION UPDATES FROM cIMPACT-NOW, THE CONSORTIUM TO INFORM MOLECULAR AND PRACTICAL APPROACHES TO CNS TUMOR CLASSIFICATION. <i>Neuro-Oncology</i> , 2018, 20, vi165-vi165.	0.6	0
24	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi237-vi238.	0.6	1
25	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	3.9	599
26	Implementing the DICOM Standard for Digital Pathology. <i>Journal of Pathology Informatics</i> , 2018, 9, 37.	0.8	93
27	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	0.6	99
28	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	0.6	35
29	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 189-194.	0.9	2
30	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. <i>Science</i> , 2017, 355, .	6.0	743
31	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	3.9	120
32	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. <i>Current Opinion in Neurology</i> , 2017, 30, 643-649.	1.8	62
33	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO and Shakespeare. <i>Acta Neuropathologica</i> , 2017, 134, 517-520.	3.9	15
34	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. <i>Neuro-Oncology</i> , 2017, 19, 1640-1650.	0.6	54
35	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> 27, 851-852.	2.1	63
36	Angioleiomyoma of the falx. <i>Journal of Radiology Case Reports</i> , 2016, 10, 8-15.	0.2	11

#	ARTICLE	IF	CITATIONS
37	Case 38-2016. <i>New England Journal of Medicine</i> , 2016, 375, 2381-2389.	13.9	3
38	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. <i>Acta Neuropathologica</i> , 2016, 131, 803-820.	3.9	12,144
39	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. <i>Neuro-Oncology</i> , 2016, 19, now181.	0.6	17
40	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). <i>Journal of Neuro-Oncology</i> , 2016, 130, 31-42.	1.4	35
41	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. <i>Nature</i> , 2016, 539, 309-313.	13.7	875
42	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 99-105.	0.8	8
43	The flowering of pathology as a medical discipline in Boston, 1892-c.1950: W.T. Councilman, FB Mallory, JH Wright, SB Wolbach and their descendants. <i>Modern Pathology</i> , 2016, 29, 944-961.	2.9	4
44	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 4-18.	0.9	81
45	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv310.	3.0	182
46	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
47	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	1.4	120
48	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	3.4	68
49	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	1.2	48
50	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. <i>Modern Pathology</i> , 2015, 28, 596-606.	2.9	55
51	Computational Pathology: An Emerging Definition. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1133-1138.	1.2	78
52	The 2013 symposium on pathology data integration and clinical decision support and the current state of field. <i>Journal of Pathology Informatics</i> , 2014, 5, 2.	0.8	14
53	Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. <i>Cell</i> , 2014, 157, 580-594.	13.5	751
54	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , 2014, 46, 161-165.	9.4	408

#	ARTICLE	IF	CITATIONS
55	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	0.6	12
56	International Society of Neuroanatomy & Neurochemistry consensus guidelines for nervous system tumor classification and grading. <i>Brain Pathology</i> , 2014, 24, 429-435.	2.1	499
57	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. <i>Cancer Discovery</i> , 2014, 4, 1299-1309.	7.7	207
58	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. <i>Science</i> , 2014, 344, 1396-1401.	6.0	3,648
59	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2029-2029.	0.8	7
60	Update on Glioma Treatments in the United States. <i>Japanese Journal of Neurosurgery</i> , 2013, 22, 590-596.	0.0	0
61	The next step in brain tumor classification: "Let us now praise famous men" or molecules?. <i>Acta Neuropathologica</i> , 2012, 124, 761-762.	3.9	35
62	An Ultra-High Speed Whole Slide Image Viewing System. <i>Analytical Cellular Pathology</i> , 2012, 35, 65-73.	0.7	9
63	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. <i>Clinical Cancer Research</i> , 2009, 15, 6430-6437.	3.2	88
64	The 2007 WHO Classification of Tumours of the Central Nervous System. <i>Acta Neuropathologica</i> , 2007, 114, 97-109.	3.9	9,898
65	MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2006, 1, 97-117.	9.6	566
66	Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 268-276.	1.2	43
67	Focus on central nervous system neoplasia. <i>Cancer Cell</i> , 2002, 1, 125-128.	7.7	130
68	Clear cell pleomorphic xanthoastrocytoma: case report. <i>Acta Neuropathologica</i> , 2001, 102, 404-408.	3.9	10
69	Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse. <i>Neurosurgery</i> , 2000, 47, 623-632.	0.6	165
70	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. <i>Neurosurgery</i> , 2000, 46, 663-669.	0.6	19
71	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. <i>Nature Medicine</i> , 1999, 5, 881-887.	15.2	309
72	Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. <i>Acta Neuropathologica</i> , 1998, 95, 287-290.	3.9	54

#	ARTICLE	IF	CITATIONS
73	Use of MIB-1 (Ki-67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 857-865.	0.9	86
74	Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. <i>Somatic Cell and Molecular Genetics</i> , 1997, 23, 221-223.	0.7	5
75	Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas. <i>Brain Pathology</i> , 1995, 5, 11-14.	2.1	33
76	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 91-95.	0.9	306
77	Glioblastoma multiforme in four siblings: A cytogenetic and molecular genetic study. <i>Journal of Neuro-Oncology</i> , 1995, 24, 251-258.	1.4	15
78	The retinoblastoma gene is involved in malignant progression of astrocytomas. <i>Annals of Neurology</i> , 1994, 36, 714-721.	2.8	211
79	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 1993, 86, 81-85.	3.9	93
80	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. <i>Brain Pathology</i> , 1993, 3, 19-26.	2.1	597